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SUMMARY
CRISPR-Cas9 systems provide powerful tools for
genome editing. However, optimal employment of
this technology will require control of Cas9 activity
so that the timing, tissue specificity, and accuracy
of editing may be precisely modulated. Anti-CRISPR
proteins, which are small, naturally occurring inhibi-
tors of CRISPR-Cas systems, are well suited for
this purpose. A number of anti-CRISPR proteins
have been shown to potently inhibit subgroups of
CRISPR-Cas9 systems, but their maximal inhibitory
activity is generally restricted to specific Cas9 homo-
logs. Since Cas9 homologs vary in important proper-
ties, differing Cas9s may be optimal for particular
genome-editing applications. To facilitate the prac-
tical exploitation of multiple Cas9 homologs, here
we identify one anti-CRISPR, called AcrIIA5, that
potently inhibits nine diverse type II-A and type II-C
Cas9 homologs, including those currently used for
genome editing. We show that the activity of AcrIIA5
results in partial in vivo cleavage of a single-guide
RNA (sgRNA), suggesting that its mechanism in-
volves RNA interaction.
INTRODUCTION
CRISPR-Cas9 systems combine a single effector protein,
Cas9, with a single-guide RNA (sgRNA) molecule to target spe-
cific DNA sequences for precise genome manipulation. Their
ability to program these systems to target any desired DNA
sequence has led to their widespread usage for creating
genomic knockouts and knockins, editing single bases, and
gene activation and silencing (Doudna and Charpentier, 2014;
Hess et al., 2017; Komor et al., 2017). However, there are con-
cerns about the ability to safely and effectively control this tech-
nology, particularly in the case of applications like gene drives
(Baltimore et al., 2015; Gantz and Bier, 2015; Hammond
et al., 2016).
One mechanism by which CRISPR-Cas9 activity can be
controlled is through the use of small, naturally occurring protein
inhibitors known as anti-CRISPRs (Borges et al., 2017; Pawluk
et al., 2018). These proteins have been shown to function as
off switches for CRISPR-Cas9 genome editing in human cells
(Lee et al., 2018; Pawluk et al., 2016; Rauch et al., 2017; Shin
et al., 2017). They have also been used to control gene activation
(CRISPRa) and gene interference (CRISPRi) in yeast and
mammalian cells (Nakamura et al., 2019) and to decrease the
toxicity of CRISPR-Cas9 delivered by an adenovirus vector to
human stem cells (Li et al., 2018). Since the methods of in vivo
delivery for CRISPR-Cas9, which include viral vectors and nano-
particles, do not have high tissue specificity, it is crucial to avoid
editing in non-targeted tissues, which would increase the risk of
unwanted side effects (Cox et al., 2015). Recently, a Cas9-ON
switch based on microRNA-dependent expression of an anti-
CRISPR protein was used to control gene editing in a cell-spe-
cific manner (Hoffmann et al., 2019), including in the tissues of
adult mice in vivo (Lee et al., 2019). These applications of anti-
CRISPRs are varied, and their potential for further development
is enormous.
While many different Cas9 proteins exist in nature, only a
few are commonly used for genome engineering applications.
These include the type II-A Cas9 proteins derived from
Streptococcus pyogenes (SpyCas9) and Staphylococcus aureus
(SauCas9) (Colella et al., 2017; Ran et al., 2015) and the type II-C
Cas9 proteins from Neisseria meningitidis (Nme1Cas9) and
Campylobacter jejuni (CjeCas9) (Ibraheim et al., 2018; Kim
et al., 2017; Lee et al., 2016; Mir et al., 2018b; Zhang et al.,
2015). These Cas9 homologs vary in features such as proto-
spacer adjacent motif (PAM) specificity, size, and off-target
activity, whichmakes eachmore or less advantageous for partic-
ular genome-editing applications. Anti-CRISPRs that target
some of these Cas9 proteins have been identified (Harrington
et al., 2017; Hynes et al., 2017; Pawluk et al., 2016; Rauch
et al., 2017), but none of these efficiently inhibit all of them.
The identification of a well-characterized, universal anti-CRISPR
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protein that could function to control Cas9 activity in a variety of
different applications—including genome editing, gene drives,
and CRISPRi/CRISPRa—would have broad utility and could
hasten the development of these technologies. Thus, the goal
of this work was to identify an anti-CRISPR with broad and
potent activity.
In this study, we investigated the spectra of inhibition of a
variety of previously described anti-CRISPRs that showed activ-
ity against type II-A (Hynes et al., 2018, 2017; Rauch et al., 2017;
Uribe et al., 2019) and type II-C (Mir et al., 2018b; Pawluk et al.,
2016) CRISPR-Cas9 systems using an efficient E. coli phage-
based assay system. We discovered that the previously identi-
fied anti-CRISPR, AcrIIA5 from Streptococcus thermophilus
phage D4276 (Hynes et al., 2017), has the broadest Cas9 inhib-
itory activity described to date, inhibiting all of the Cas9 proteins
commonly used in genome-editing applications.
RESULTS
AcrIIA5 Inhibits a Broad Spectrum of Cas9 Proteins
A key initial goal of this work was to develop a system to identify
anti-CRISPRs with the broadest possible spectrum of activity for
use in Cas9-based technologies. To quantitatively compare the
specificity profiles of a large number of anti-CRISPR proteins,
we expanded upon a previously described phage-targeting
assay in which Cas9 from Geobacillus stearothermophilus
(GeoCas9) was engineered to prevent infection by E. coli phage
Mu (Harrington et al., 2017). In this assay, GeoCas9 was co-ex-
pressed with an sgRNA that targets phage Mu and prevents its
replication by cleaving its genome. In the current work, we ex-
pressed a diverse group of Cas9 homologs (Figures 1A and
1B) in E. coli, each engineered to target phage Mu. These
Cas9 homologs include those commonly used in genome-edit-
ing applications, including SpyCas9, SauCas9, CjeCas9, and
Nme1Cas9.We also chose six additional Cas9 homologs distrib-
uted across the phylogeny of Cas9s occurring in bacteria (Fig-
ure 1A). All three subtypes (II-A, II-B, and II-C) were represented
among these Cas9s, which range in pairwise sequence identity
from 19% to 66% and utilize a variety of PAM sequences
(Figure 1B).
We tested 10 previously identified anti-CRISPRs in the phage
Mu targeting assay, including four that were shown to inhibit type
II-A and five that inhibit type II-C CRISPR-Cas systems. As seen
in Figure 1C, the targeted cleavage activity of each of these Cas9
proteins reduced the plaquing efficiency of phage Mu by at least
105-fold compared to strains expressing the sameCas9 proteins
with non-targeting sgRNA (Figure 1C). The co-expression of anti-
CRISPRs completely reversed the Cas9-mediated reduction of
plaquing efficiency in some cases (Figure 1C). However, in other
cases, anti-CRISPR co-expression caused no increase or only a
partial increase in plaquing efficiency. The level of phageMu pla-
quing in the presence of a particular Cas9/anti-CRISPR combi-
nation provides a quantitative measure of the effectiveness of
the anti-CRISPR in inhibiting a given Cas9 homolog. Some
anti-CRISPRs, such as AcrIIA4, are very specific, inhibiting
only one or a few CRISPR-Cas9 systems, while others, such
as AcrIIC1, strongly inhibited many different Cas9s (Figure 1D).
Overall, the results in Figure 1D show that the strength of anti-
CRISPRs may vary over many orders of magnitude, and the
specificity profile of each anti-CRISPR is unique.
In contrast to all of the other anti-CRISPRs tested, AcrIIA5 was
able to completely inhibit every type II-A and II-C Cas9 tested,
failing to block only the type II-B Cas9 from Francisella novicida
(Figures 1C and 1D). AcrIIA5 was the only anti-CRISPR able to
block the highly divergent CdiCas9, emphasizing its unusually
broad activity. A previous in vitro study noted the ability of
AcrIIA5 to inhibit CjeCas9 and a homolog of AcrIIA5 to inhibit
Nme1Cas9 (Marshall et al., 2018). The uniquely broad specificity
of AcrIIA5 inspired us to further investigate its properties.
AcrIIA5 Inhibits Genome Editing Mediated by Type II-A
and Type II-C CRISPR Systems in Mammalian Cells
Although AcrIIA5 was previously shown to inhibit genome editing
mediated by SpyCas9 and Streptococcus thermophilus Cas9
(St1Cas9) in mammalian cells (Hynes et al., 2017), its activity
against other Cas9 proteins in genome-editing applications
had not been tested. To determine if AcrIIA5 could inhibit
genome editing mediated by the four Cas9 homologs commonly
used for genome-editing purposes in mammalian cells, we
transiently co-transfected mouse Neuro-2a (N2a) (Figure 2A) or
human HEK293T (Figure 2B) cells with plasmids expressing
anti-CRISPR proteins, Cas9s and their respective sgRNAs de-
signed to target specific genomic sites. Tracking of indels by
decomposition (TIDE) analyses (Brinkman et al., 2014) revealed
that AcrIIA5 inhibited the activities of SpyCas9, Nme1Cas9,
SauCas9, and CjeCas9. These results were confirmed using a
previously described T7 endonuclease I (T7E1) assay (Figure 2C)
(Pawluk et al., 2016). We further probed the ability of AcrIIA5 to
inhibit Cas9 homologs using a variation of the traffic light reporter
(TLR) system (Certo et al., 2011), which contains an artificial lo-
cus harboring Cas9 target sites. In this assay, an out-of-frame
mCherry gene is targeted for Cas9 editing, resulting in a subset
of indels that restore the proper reading frame for mCherry,
thereby generating a fluorescent signal. Co-transfection of
Cas9 homologs and their respective sgRNAs targeting the TLR
locus resulted in cells with mCherry expression ranging from
5% to 20%, depending on the Cas9 used for editing. Expression
of AcrIIA5 by transient transfection reduced the editing at the
TLR locus by all of the Cas9 homologs tested (Figure 2D). Collec-
tively, these results show that AcrIIA5 efficiently inhibits the
in vivo genome-editing activity of four diverse Cas9 proteins in
both bacterial and mammalian cells. Furthermore, AcrIIA5 in-
hibits genome editing with similar potency to previously utilized
anti-CRISPRs.
AcrIIA5 Activity Prevents DNA Binding and Leads to
sgRNA Cleavage
To investigate howAcrIIA5 inhibits Cas9 activity, we developed a
luminescence-based bioassay in which we targeted the catalyt-
ically inactive dSpyCas9 (Gilbert et al., 2014) to a constitutively
expressed artificial promoter that drives expression of the
luxCDABE luminescence genes in E. coli (Figure 3A). sgRNA-tar-
geted binding of dSpyCas9 to the promoter of the luxCDABE
operon repressed transcription, and no luminescence was de-
tected (Figure 3B). Expression of AcrIIA5 relieved this repression,
leading to an increase in luminescence and showing that DNA






Figure 1. AcrIIA5 Displays a Broad Spectrum of Activity against Cas9 Proteins
(A) Phylogenetic tree of a non-redundant dataset of Cas9 proteins with <90% sequence identity. Cas9 homologs tested for AcrIIA5 inhibitory activity are indicated
at the ends of branches on the tree. Clades are colored by Cas9 subtype.
(B) Summary of Cas9 proteins used in the phage Mu targeting assays. The length in amino acids, subtype classification, PAM sequence, and all-versus-all
pairwise sequence identity are shown.
(C) Representative E. coli phage Mu plaque assays for each of the Cas9 systems tested. Ten-fold serial dilutions of phage Mu lysate were plated on lawns
expressing the anti-CRISPR noted above the columns. Representative pictures of at least three biological replicates are shown.
(D) The inhibitory activity of all tested anti-CRISPRs against diverse Cas9 homologs is represented. The darkness of the cell in the table indicates the degree of
inhibition of the Cas9 homolog by the indicated anti-CRISPR, with the darkest cell representing >106-fold inhibition of the Cas9 system (i.e., plaquing efficiency of
phage Mu increases >106-fold in the presence of the anti-CRISPR). The lightest-shaded cells indicate that the given anti-CRISPR displayed no inhibition of the
Cas9 homolog. This figure represents data obtained through at least three biological replicates of each assay.
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binding was inhibited. Similarly, expression of AcrIIA4, which
was previously shown to inhibit SpyCas9 DNA binding (Dong
et al., 2017; Shin et al., 2017; Yang and Patel, 2017), also led
to an increase in luminescence. By contrast, expression of
AcrIIC1, which does not inhibit SpyCas9 (Harrington et al.,
2017; Pawluk et al., 2016), showed no increase in luminescence,
as expected. These results demonstrate that AcrIIA5 blocks
binding of dSpyCas9 to target DNA and impedes its function
as a transcriptional repressor.
After co-expression of His6-tagged Nme1Cas9 and AcrIIA5,
AcrIIA5 did not co-elute with Nme1Cas9, while a control, AcrIIC1,
did co-elute (Figure 3C). Nevertheless, Nme1Cas9 expressed in
the presence of AcrIIA5 was unable to cleave DNA in vitro (Fig-
ure 3D). Thus, co-expression of AcrIIA5 with Nme1Cas9 caused
a loss of activity even though the anti-CRISPR did not form a sta-
ble complex with Cas9. Electrophoretic examination of the
sgRNA bound to Nme1Cas9 purified in the presence of AcrIIA5
surprisingly showed that a sizable proportion was smaller
compared to the sgRNA bound to Nme1Cas9 expressed without
AcrIIA5 or with AcrIIC1 (Figures 3C, S1A, and S1B). The full-
length and cleaved sgRNA molecules seen in these gels were




Figure 2. AcrIIA5 Inhibits Genome Editing Mediated by Nme1Cas9, SpyCas9, CjeCas9, and SauCas9 in Mammalian Cells
(A) Co-transfection of Cas9 orthologs and their respective sgRNA expression plasmids show inhibition of genome editing by AcrIIA5 in mammalian cells. AcrIIC1
and AcrIIA4 are used as positive controls for SauCas9 and SpyCas9 inhibition, respectively. Genome editing was quantified using TIDE analysis (Brinkman et al.,
2014) in mouse cells.
(B) Co-transfection of Cas9 orthologs and their respective sgRNA expression plasmids targeting either the ARHGEF9 (SpyCas9 and Nme1Cas9) or AAVS1 locus
(CjeCas9) show inhibition of genome editing by AcrIIA5 in a human HEK293T cell line. Editing was quantified by TIDE analysis (Brinkman et al., 2014). AcrIIC1 and
ArIIA4 were used as positive controls for type II-C (Nme1Cas9 and CjeCas9) and type II-A (SpyCas9) inhibition, respectively.
(C) Genome editing in the cell lines used in (A) and (B) were analyzed by T7E1 experiments. The image is representative of at least three replicates.
(D) Co-transfection of Cas9 orthologs, their respective sgRNAs, and AcrIIA5 expression plasmids in a cell line stably expressing TLR-MCV1, a variation of the
traffic light reporter (TLR) system (Certo et al., 2011). TLR-MCV1 contains an artificial locus harboring target sites for a wide range of Cas9 orthologs. Upon
double-strand break induction by a Cas9 ortholog, a subset of non-homologous end-joining (NHEJ) repair events generate indels that place mCherry in frame.
The percentage (%) of mCherry cells was used as an estimate of genome-editing efficiency. Anti-CRISPRs used as controls were AcrIIC1 for type II-C Cas9
homologs (Nme1Cas9 and CjeCas9) and AcrIIA4 for type II-A SpyCas9.
In (A), (B), and (D), the values and error bars represent the mean ± the SD of three independent biological replicates.
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Figure 3. AcrIIA5 Prevents DNA Binding and Leads to sgRNA Cleavage
(A) Overview of the luminescence-based bioassay. Mutations in the catalytic domains of SpyCas9 yield a dead variant (dSpyCas9) that binds but does not cleave
DNA. When dSpyCas9 is programmed to target the promoter controlling the lux expression, binding of dSpyCas9 to the promoter blocks transcription. Anti-
CRISPR proteins can block the binding of dSpyCas9 to the target DNA, restoring transcription and expression of the lux cassette.
(B) The luminescence signal displayed by cells expressing dSpyCas9 targeting a promoter driving lux expression in the presence of the indicated anti-CRISPR is
shown. Data represent the mean and SD of luminescence measurements for three replicates.
(C) His6-Nme1Cas9 was co-expressed and co-purified with pCDF-1b (no anti-CRISPR [-]), AcrIIC1, or AcrIIA5. Ribonucleoprotein complexes were analyzed
by SDS-PAGE gel (top) and polyacrylamide/Urea gel (bottom). The name of the anti-CRISPR co-expressed with Nme1Cas9 is indicated at the top of the SDS-
PAGE gel.
(D) DNA cleavage mediated by Nme1Cas9 co-expressed with AcrIIA5. A plasmid containing the target protospacer was linearized and incubated with the
indicated Nme1Cas9/anti-CRISPR combination at 37C. Samples were taken at the indicated time points and analyzed by DNA gel electrophoresis.
(E) A schematic of the Nme1Cas9 sgRNA with bound target protospacer DNA is shown. The positions of RNA cleavage detected by sequencing in the sgRNA
bound to Nme1Cas9 co-expressedwith AcrIIA5 are indicated. The sgRNA secondary structure shown is predicted from other Cas9/sgRNA structures. The image
is representative of at least three replicates.
(F) Activity of AcrIIA5 against Cas9 bound to modified crRNA and tracrRNA. A ribonucleoprotein complex composed of SpyCas9 and modified or unmodified
crRNA/tracrRNA was electroporated into HEK293T cells (No Acr) or HEK293T cell line stably expressing AcrIIA5. Efficiency of genome editing at the genomic
VEGFA target site was measured by TIDE analysis (Brinkman et al., 2014). The bar graph represents the data plotted as mean of three replicates with SD.
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found that a portion of the Nme1Cas9 co-expressed with AcrIIA5
was bound to full-length sgRNA that was indistinguishable from
that of Nme1Cas9 controls, but it was also frequently bound to
truncated forms (Figure S1B). These truncations mapped to
stem-loop 1 and stem-loop 2 of the sgRNA (Figures 3E and
S1C). It was recently shown that Nme1Cas9 can mediate RNA
cleavage that is catalyzed by the Cas9 HNH endonuclease
domain (Rousseau et al., 2018). However, the formation of the
truncated sgRNA molecules seen here was not mediated by
either of the nuclease domains of Nme1Cas9 (Figure S1D).
To investigate the relationship between AcrIIA5 activity and
CRISPRRNA (crRNA) in a genome-editing application inmamma-
lian cells, we tested its ability to inhibit editing efficiency in the
presence of chemically modified crRNA/trans-activating crRNA
(tracrRNA) molecules that were previously described (Mir et al.,
2018a). In a cell line that stably expresses AcrIIA5, editing effi-
ciency was completely abrogated when an unmodified guide
(C0:T0) was used (see STAR Methods for details of the modified
RNA molecules) but was only partially compromised (3-fold)
when an RNase-resistant heavily modified guide (C20:T2) was
used (Figure 3F). The protection from AcrIIA5 activity provided
by chemical modification of the crRNA/tracrRNA is consistent
with this anti-CRISPR interactingwithRNA.Acaveat to this exper-
iment is that the unmodified RNAmediated genome editing much
less efficiently (5-fold) than the modified RNA. However, given
that TIDE methodology can detect editing levels of 1%–2%
(Brinkman et al., 2014), and editing by Cas9 bound to unmodified
RNA was undetectable, we estimate that AcrIIA5 reduced editing
mediated by unmodified RNA by at least 15-fold, while that medi-
ated by modified RNA was only reduced by 3-fold.
sgRNA Cleavage Is a Conserved Feature of AcrIIA5
Homologs
Despite extensive efforts, AcrIIA5 could not bepurified in a soluble
and active formon its own. In an effort to circumvent this problem,
we also cloned and expressed five additional AcrIIA5 familymem-
bers (Figures S2A and S2B), which ranged from 87% to 48% in
sequence identity at the amino acid level from the homolog from
S. thermophilus phage D4276 that we characterized here.
Although each of these homologs robustly inhibited all Cas9s
tested (Figure S2C) and were also well expressed in E. coli (Fig-
ure S2D), none could be purified in a soluble and active form.
Thus, wewere unable to carry out the detailed in vitro experiments
necessary to further elucidate the AcrIIA5 inhibitory mechanism.
To address the question of whether sgRNA cleavage is a
consistent feature of the AcrIIA5 family, we purified Nme1Cas9
co-expressed with each of the five AcrIIA5 homologs described
above. Notably, the sgRNA co-purifying in these Nme1Cas9
preparations displayed similar levels of partial cleavage in every
case (Figure S2E). To establish that sgRNAcleavagewas not due
to a unique feature of Nme1Cas9, we also co-expressed the
AcrIIA5 homologs with SpyCas9 and purified the resulting
Cas9/sgRNA complexes. The sgRNA molecules associated
with SpyCas9 were also cleaved in the presence of each of the
AcrIIA5 homologs (Figure S2F).
Finally, we constructed three AcrIIA5 mutants bearing amino
acid substitutions at residues potentially involved in catalysis
(Figure S2A). Two of these mutants displayed no inhibitory activ-
ity against all tested Cas9 homologs (Figures S3A and S3B).
Interestingly, the fourth mutant (H66N70H73) was fully active
against SpyCas9 but was unable to inhibit the other Cas9 homo-
logs. This indicates that there may be distinct regions of AcrIIA5
responsible for binding to different Cas9 homologs. Purified
Nme1Cas9 that was co-expressed with the inactive mutants
was not associated with cleaved sgRNA, supporting the connec-
tion between AcrIIA5 inhibition of Cas9 and sgRNA cleavage
(Figure S3C).
DISCUSSION
AcrIIA5 is a remarkably broad specificity anti-CRISPR that func-
tions through a uniquemechanism. The co-expression of AcrIIA5
with Nme1Cas9 results in the truncation of the sgRNA from the 30
end. This sgRNA truncation was seen consistently in six different
AcrIIA5 family members when co-expressed with Nme1Cas9 or
SpyCas9. The enigmatic feature of this sgRNA truncation is that
the relative amounts of truncated products vary in different ex-
periments, as do the apparent numbers of truncated products
(i.e., the number of higher-mobility bands seen in the gels) (Fig-
ures 3C, S1B, S1D, S2E, S2F, and S3C). In addition, there is al-
ways some sgRNA remaining bound to Cas9 co-expressed with
AcrIIA5 that displays the mobility of full-length sgRNA in dena-
turing polyacrylamide/Urea gels, and sequencing confirmed
that this sgRNA is indistinguishable from that bound to Nme1-
Cas9 in the absence of AcrIIA5 (Figure S1C). We conclude that
sgRNA cleavage alone cannot account for the potent inhibitory
activity of AcrIIA5. Rather, the action of AcrIIA5 may partially
dislodge the sgRNA from Cas9, leaving it prone to digestion by
intracellular RNases. The portion of the sgRNA that we observe
to be digested, stem-loops 1 and 2, are the more exposed parts
of the sgRNA in the Cas9/sgRNA complex. We speculate that
this AcrIIA5-induced effect on the sgRNA interaction with Cas9
could be due to an irreversible conformational change or a
post-translational modification. An anti-CRISPR has been
described that inhibits Cas12a by acetylating a key residue in
the DNA-binding interface (Dong et al., 2019).
We cannot rule out that AcrIIA5 itself does have nuclease ac-
tivity, as there are many examples of small ribonucleases asso-
ciated with toxin-antitoxin systems that specifically digest
mRNA, tRNA, or rRNA (Masuda and Inouye, 2017), and anti-
CRISPR AcrVA1 is a specific crRNA nuclease (Knott et al.,
2019; Zhang et al., 2019). However, we were unable to detect
any resemblance between AcrIIA5 and ribonucleases by per-
forming extensive Position-Specific Iterative Basic Local Align-
ment Search Tool (PSI-BLAST) (Altschul et al., 1997) searches
or through analysis using HHpred (Söding et al., 2005). Further-
more, no structural similarity to ribonucleases was predicted by
either the Iterative Threading ASSEmbly Refinement (I-TASSE)
(Yang and Zhang, 2015) or Phyre (Kelley et al., 2015) protein
structure prediction servers. Some role for sgRNA in the activity
of AcrIIA5 is supported by the relative insensitivity of modified
sgRNA-bound Cas9 to inhibition by this anti-CRISPR. Chemical
modifications may provide protection from cleavage by AcrIIA5,
prevent RNA recognition by AcrIIA5, or protect sgRNA from
intracellular RNases when it is dislocated from Cas9 by AcrIIA5
activity.
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In summary, we have characterized AcrIIA5, a potent inhibitor
of all type II-A and type II-C Cas9 homologs tested. This anti-
CRISPR functions in a distinct manner from other characterized
Cas9 inhibitors. As the number of described anti-CRISPRs has
rapidly increased in recent years, the contemplated biotechno-
logical uses for them have also grown. Since different Cas9
homologs possess distinct properties (e.g., small size, thermo-
tolerance, and distinct PAM specificities) that make them more
suited for particular applications, the identification of a single
anti-CRISPR that can potently inhibit the broadest possible
range of Cas9 homologs is of great value.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins
Gibson Assembly Master mix New England Biolabs #E2611
Phusion High-Fidelity DNA Polymerase ThermoFisher Scientific #F530
DpnI-FD ThermoFisher Scientific #FD1703
BsaI-HFv2 New England Biolabs #R3733
Hifi-Assembly DNA Assembly New England Biolabs #E5520
SYBRTM Gold ThermoFisher Scientific #S11494
T7 Endonuclease 1 New England Biolabs #M0302L
DMEM (Medium for mammalian cell culture) GIBCO #11965092
Fetal Bovine Serum (For mammalian cell culture) Sigma Aldrich #F4135
Penicillin-Streptomycin (For mammalian cell culture) Sigma Aldrich #P4333
PolyFect transfection reagent QIAGEN #3011
High Fidelity 2X PCR Master Mix New England Biolabs #M0541S
DreamTaq Green PCR Master Mix 2X ThermoFisher Scientific #K1081
DNA Gel Elution Buffer New England Biolabs #E7324A
SUPERase, In RNase Inhibitor ThermoFisher Scientific #AM2696
Critical Commercial Assays
DNA Clean & Concentrator-5 Zymo Research #D4004
NEBNext Small RNA Library Prep Set for Illumina New England Biolabs #E7330
DNeasy Blood and Tissue Kit QIAGEN #69504
Ni-NTA agarose resin QIAGEN #30210
Superdex 200 10/300 GE Healthcare #28990944
Experimental Models: Cell Lines
Neuro-2a ATCC CCL-131
Human HEK293T ATCC ATCC CRL-3216
HEK293T-TLR-MCV1 variant This study N/A
HEK293T-TLR-MCV1-AcrIIA5 This study N/A
Oligonucleotides
See Table S1 for sequences of sgRNAs used This study N/A
N66H70N73aA5F GAAATCCGTCTGTCCAATgcCAGTGCTGAT
gcTAAATACgcTGATCTTGAGAATGGGCG
Integrated DNA Technologies N/A
N66H70N73aA5R CGCCCATTCTCAAGATCAgcGTATTTAgc
ATCAGCACTGTcATTGGACAGACGGATTTC
Integrated DNA Technologies N/A
D50R62aA5F AAGTATGAAGGcTTCTGCCTATAAAGACTTTG
GAAAATATGAAATCgcTCTGTCCAATCA
Integrated DNA Technologies N/A
D50R62aA5R TGATTGGACAGAgcGATTTCATATTTTCCAAAG
TCTTTATAGGCAGAAgCCTTCATACTT
Integrated DNA Technologies N/A
D74K8588aA5F AAATACCATGcTCTTGAGAATGGGCGTCTTAT
CGTGAACATCgcAGCATCAgcGCTGAAC
Integrated DNA Technologies N/A
D74K8588aA5R GTTCAGCgcTGATGCTgcGATGTTCACGATAA
GACGCCCATTCTCAAGAgCATGGTATTT
Integrated DNA Technologies N/A
Recombinant DNA
pGeoCas9-sgRNAMu Harrington et al., 2017 https://benchling.com/s/
seq-lXSEQMlloSIZmGtpNsld/edit
pHpaCas9sgRNAMu Lee et al., 2018 N/A
pNme1Cas9sgRNAMu Thavalingam et al., 2019 N/A
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
pCjeCas9sgRNAMu Thavalingam et al., 2019 N/A
pBoeCas9sgRNAMu This study N/A
pKlaCas9sgRNAMu This study N/A
pCdiCas9sgRNAMu This study N/A
pSauCas9sgRNAMu This study N/A
pSpyCas9sgRNAMu This study N/A
pFnoCas9sgRNAMu This study N/A
pCDF-1b Novagen #71330-3
pCDF-ACRE2 Harrington et al., 2017 N/A
pCDF-ACRIIC1Nme Harrington et al., 2017 N/A
pCDF-ACRIIC2Nme Thavalingam et al., 2019 N/A
pCDF-ACRIIC3Nme This study N/A
pCDF-ACRIIC4Hpa Lee et al., 2018 N/A
pCDF-ACRIIC5Smu Lee et al., 2018 N/A
pCDF-ACRIIA2Lmo This study N/A
pCDF-ACRIIA3Lmo This study N/A
pCDF-ACRIIA4Lmo This study N/A
pCDF-ACRIIA5SthD4276 This study N/A
pCDF-ACRIIA5SthD1126 This study N/A
pCDF-ACRIIA5Efa This study N/A
pCDF-ACRIIA5Dpi This study N/A
pCDF-ACRIIA5Lsa This study N/A
pCDF-ACRIIA5G572 This study N/A
pCRISPathBrick Cress et al., 2015 Addgene #65006
pCM-str J. Nodwell Lab N/A
TOPO vector ThermoFisher Scientific #K4500-01
6x-His-tagged Nme1Cas9-sgRNA in pMCSG7 Pawluk et al., 2016 N/A
6x-His-tagged SpyCas9-sgRNA This study N/A
SpyCas9-sgRNA Ran et al., 2013 Addgene #62988
SauCas9-sgRNA Ran et al., 2015 Addgene #61591
pEJS24-pCSDest2-SpyCas9-NLS-3XHA-NLS Bolukbasi et al., 2015 Addgene #69220
pEJS424-pCSDest2-NmeCas9-NLS-3XHA-NLS Pawluk et al., 2016 Addgene #87448
pEJS485-pCSDest2-SauCas9 S. Wolfe lab N/A
pX404-CjeCas9 F. Zhang lab Addgene #68338
pEJS433 pCSDest2-AcrIIC1 Pawluk et al., 2016 Addgene #85679
p611-pCSDest2-AcrIIA4 This study N/A
pEJS1004-pCSDest2-AcrIIA5-NLS-FLAG This study N/A
pEJS1005-Lenti-mammalian c.o.AcrIIA5-FLAG-NLS-HygR This study N/A
Software and Algorithms
FigTree 1.4.3 Institute of Evolutionary Biology,
University of Edinburgh
http://tree.bio.ed.ac.uk/software/
FlowJo v10.4.1. FlowJo LLC N/A
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CONTACT FOR REAGENT AND MATERIALS AVAILABILYITY
Please direct any requests for further information or reagents generated in this study to the lead contact, Alan R. Davidson (alan.
davidson@utoronto.ca). All unique/stable reagents generated in this study are available from the Lead Contact without restriction.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Escherichia coli BB101 (DE3)
E. coli BB101 (DE3) cells were used for protein expression for in vivo phage targeting experiments, in vitro studies, and RNP expres-
sion and purification. Cells were cultured in Luria broth (LB) at 37C. To ensure plasmid maintenance, LB media was supplemented
with chloramphenicol (34 mg/mL) and streptomycin (34 mg/mL) for the co-expression of the plasmid expressing Cas9s and the Anti-
CRISPR proteins for the phage targeting experiments. For RNP expression and purification in the presence of Anti-CRISPR proteins,
ampicillin (100 mg/mL) and streptomycin (34 mg/mL) were used for plasmid maintenance.
Phage
E. coliMu phage was propagated at 30C. Mu phage production was induced by increasing the temperature to 45C for 15 minutes
and transferred to 37C until cell lysis occurred. Mu phage was stored at 4C.
Cell lines
HEK293T and Traffic Light Reporter (TLR) cell line (TLR-MCV1, unpublished) were cultured in Dulbecco’s modified Eagle’s minimum
essential medium (DMEM; Life Technologies) supplemented with 10% (vol/vol) FBS (Sigma) and 1% Penicillin/Streptomycin.
Neuro-2a cells were cultured at 37C, 5% CO2in DMEM + 10% FBS + 1% Penicillin/Streptomycin.
METHOD DETAILS
Phylogenetic analysis of Cas9 proteins
The Neisseria meningitidis Cas9 sequence from strain 8013 (accession number PHP22510) was used to query the NCBI complete
bacterial genome database (four psiBLAST iterations, max target sequences 30,000). Protein sequences corresponding to
unique accession numbers (e-value < 0.1) were collected. A non-redundant set of proteins was compiled by filtering out proteins
with > 90% sequence identity. The resulting sequences were aligned using MAFFT (Katoh et al., 2002) and Clustal Omega (Sievers
et al., 2011) to generate multiple sequence alignment and tree files (Newick format). Phylogenetic trees were visualized using FigTree
1.4.3 (http://tree.bio.ed.ac.uk/software/).
Plasmid construction
DNA sequences encoding anti-CRISPR genes were cloned into pCDF-1b (Novagen) for in vivo phage Mu targeting experiments,
luminescence assays, and co-expression in E. coli. Mutations were introduced into the AcrIIA5 open reading frame contained in
the pCDF-1b-derived plasmid by site-directed mutagenesis. For each mutation, two 40-bp complementary primers containing
desired mutations were designed. The PCR reaction was conducted using Phusion High-Fidelity DNA Polymerase (Thermo Fisher
Scientific), followed by DpnI digestion. The resulting DNA product was used to transform E.coli DH5a cells. Plasmids were isolated
from streptomycin resistant colonies and all mutations were verified by sequencing.
The plasmids expressing GeoCas9 and HpaCas9 used for phage targeting assays were previously described (Harrington et al.,
2017; Lee et al., 2018). The non-targeting plasmids expressing Cas9 orthologs were constructed from pGeoCas9-sgRNA (Harrington
et al., 2017), replacing the Cas9 coding sequence and the sgRNA scaffolds (listed in Table S1). The Cas9 homologs from Kiloniella
laminariae and Brackiella oedipodis, which have not been previously described, were cloned and expressed in the same manner as
the other Cas9 proteins. sgRNA and PAM sequences were determined using the same approach as used previously by our group
(Lee et al., 2018). The detailed characterization of these Cas9 homologs will be described in a future publication.
The sgRNA scaffolds were ordered as gblocks (IDT) and were cloned into the plasmid using a Gibson Assembly reaction (NEB). A
unique BsaI restriction site was included in the non-targeting plasmids to clone DNA fragments encoding a crRNA that targets phage
Mu or the J23119 promoter (http://parts.igem.org/Part:BBa_J23119). These DNA fragments were generated by phosphorylation and
annealing of ssDNA oligos (Eurofins Genomics).
The AcrIIA5 mammalian expression vectors were generated by cloning a codon-optimized anti-CRISPR sequence into pCDest2
(pEJS1004-pCDest-ACRIIA5-FLAG-NLS) or a lentiviral vector (pEJS1005-pLenti-AcrIIA5-FLAG/NLS-HygR) using Hifi-Assembly
(NEB). The plasmid used for the mouse cell line genome editing experiments was previously described for AcrIIC1 (Pawluk et al.,
2016; Addgene #85679). The same plasmid was used for expression of AcrIIA4 and AcrIIA5. Addgene plasmids were used for the
SpyCas9-sgRNA (#62988) and SauCas9-sgRNA (#61591) experiments.
Expression plasmid 6x-His-tagged SpyCas9-sgRNA was constructed from 6x-His-tagged Nme1Cas9-sgRNA in pMCSG7 (Paw-
luk et al., 2016), replacing the Cas9 coding sequence and the sgRNA scaffolds. Both plasmids were used for the co-expression and
co-purification experiments.
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In vivo phage Mu plaquing assays
E. coli BB101 cells were co-transformed with plasmids expressing Cas9-sgRNA combinations targeting phage Mu and a pCDF-1b
plasmid expressing the different anti-CRISPR proteins. Cells containing both plasmids were sub-cultured in LB supplemented with
chloramphenicol and streptomycin and grown for two hours, at which point anti-CRISPR expression was induced with 0.01mM IPTG
for 3h. Cells were then mixed with soft LB-agar and top-plated on LB supplemented with both antibiotics and 200 ng/mL aTc, 0.2%
arabinose, and 10 mM MgSO4. Serial dilutions of phage Mu were spotted on top and the plates were incubated overnight at 37
C.
Experiments were performed in triplicate. To confirm anti-CRISPR expression in E. coli, 500 mL of cells after IPTG induction were
collected by centrifugation, resuspended in 100 mL SDS loading buffer and analyzed by SDS-PAGE on a 15% Tris-Tricine gel, fol-
lowed by Coomassie Blue staining.
Cell culture, transfection, and stable cell line construction
Cells were cultured in Dulbecco’s modified Eagle’s minimum essential medium (DMEM; Life Technologies) supplemented with 10%
(vol/vol) FBS (Sigma) and 1% P/S (Life Technologies). Plasmids transfection was performed using Polyfect reagent as described
(Pawluk et al., 2016). Transient transfection of 100 ng Cas9, 100 ng sgRNA, and either 200 ng or 300 ng of anti-CRISPR were
used for HEK293T and a Traffic Light Reporter (TLR) cell line (TLR-MCV1, unpublished), respectively. For the ‘‘NoAcr’’ conditions
200 ng or 300 ng of a stuffer plasmid was included in the transfection to keep the total amount of DNA constant. Lentiviral transduc-
tion was performed as described (Ma et al., 2016). Briefly, viruses were produced and collected by transfecting HEK293T (ATCC) with
the lentiviral vector plasmid, pEJS1005- pLenti-c.o.AcrIIA5-FLAG-NLS-HygR that expresses AcrIIA5 (driven by the EF1-ɑ promoter)
and packaging helper plasmids (VSV-G and DR8.2). HEK293T and HEK293T-TLR-MCV1 target cells were transduced with viruses
and then selected with hygromycin, resulting in HEK293T-AcrIIA5 and HEK293T-TLR-MCV1-AcrIIA5 cell lines.
Neuro-2a cells [cultured at 37C, 5%CO2 in DMEM+10%FBS+ 1%Penicillin/Streptomycin (GIBCO)] were transiently transfected
with 250 ng of either SpyCas9/sgRNA targeting the NPC1 locus or SauCas9/sgRNA targeting the NPC1 locus, and 250 ng of anti-
CRISPR expressing plasmid.
Electroporation of mammalian cells
TheHEK293T cells or HEK293T-AcrIIA5 cells were electroporated using theNeon transfection system (ThermoFisher) with an in vitro-
formed ribonucleoprotein complex of SpyCas9, crRNAs (C0 or C20), and tracrRNAs (T0 or T2) that were synthesized as described
previously (Mir et al., 2018a). Briefly, 80 pmol SpyCas9, 100 pmol crRNA, and 100 pmol tracrRNA were incubated in Buffer R at room
temperature for 30 minutes and electroporated into 100,000 cells.
Flow cytometry
The mCherry-positive TLR-MCV1 cells were analyzed on a MACSQuant VYB from Miltenyi Biotec using a yellow laser with a
561 nm excitation and emission 615/20 nm filter. FlowJo v10.4.1. was used for gating single cells based on FSC-A and FSC-H after
removal of debris. The percentage of cells expressing mCherry was used to estimate the Cas9-mediated editing efficiency.
Indel analysis by T7E1 and TIDE
Genomic DNA from cells was harvested using DNeasy Blood and Tissue kit (QIAGEN) according to the manufacturer protocol. PCR
was used to amplify the locus surrounding the targeted site [DreamTaq Green PCR Master Mix 2X (Thermo Scientific)]. The PCR re-
actions were subsequently used for T7E1 assay as previously described (Pawluk et al., 2016). The ampliconswere also sequenced by
Sanger sequencing using the forward amplification primer. TIDE decomposition software (https://tide.deskgen.com/) was used to
assess editing percentage for all transfections (Brinkman et al., 2014).
Luminescence assay
DNA encoding a crRNA targeting the constitutive promoter region of J23119 was cloned into the BsaI site of the pCRISPathBrick
plasmid (Cress et al., 2015). This plasmid was co-transformed into E. coli BL21 cells with pCM-str, a plasmid in which the J23119
artificial promoter drives constitutive expression of the luxCDABE operon from Photorhabdus luminescens (Winson et al., 1998).
These cells were then co-transformed with a pCDF-1b plasmid expressing the anti-CRISPR proteins and a protospacer targeting
the J23119 promoter. Cells containing the three plasmids were grown in LB supplemented with kanamycin, chloramphenicol and
streptomycin until they reached an optical density at 600 nm (OD600) of 0.6. The cultures were then diluted to an OD600 of 0.1 in
LB containing 200 ng/mL aTc, 0.2% arabinose and 0.01 mM IPTG, and 100 ml was dispensed into a 96-well plate. The plate was
incubated with shaking at 37C using a Synergy H1 reader controlled by Gen5 2.09 software (BioTek Instruments Inc.), and the
OD600 and luminescence was monitored for 24 hours.
Co-expression and co-purification of Nme1Cas9/sgRNA and anti-CRISPR
E. coli BB101 cells were co-transformed with 6x-His-tagged Nme1Cas9/sgRNA in pMCSG7 (Pawluk et al., 2016) or 6x-His-tagged
SpyCas9/sgRNA in pMCSG7 and a pCDF-1b vector encoding untagged anti-CRISPR protein. Cells were grown in LB at 37C to an
OD of 0.8. Protein expression was induced by the addition of 1mM IPTG, and the cells were incubated for an additional 3 hours at
37C. Cells were collected by centrifugation, resuspended in binding buffer [50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 5% glycerol,
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20 mM imidazole], and lysed by sonication. Clarified lysates were incubated with Ni-NTA agarose (QIAGEN) for 30 minutes at 4C,
washed with binding buffer supplemented with 30 mM imidazole, and bound protein was eluted with binding buffer supplemented
with 300mM imidazole. The purified ribonucleoprotein complexes were analyzed by SDS-PAGE using a 15%Tris-Tricine gel, and the
proteins were visualized using Coomassie stain. The co-purifying sgRNA was examined using a denaturing 12.5% polyacrylamide/
Urea gel and visualized by SYBRTM Gold (ThermoFisher Scientific) staining.
For size exclusion chromatography experiments, a Superdex 200 10/300 column was used for Nme1Cas9-sgRNA and
Nme1Cas9sgRNA purified from cells expressing the AcrIIA5. Fractions were analyzed on a 15%PAGE gel and stained with Coomas-
sie Blue. The co-purifying sgRNA was examined using a denaturing 12.5% polyacrylamide/Urea gel and visualized by SYBRTM Gold
(ThermoFisher Scientific) staining.
In vitro DNA cleavage assays
DNA cleavage reactions were conducted in Cleavage Buffer [75 mM NaCl, 20 mM Tris (pH 7.5), 5 mM MgCl2, 1 mM TCEP] at 37
C.
Cas9/sgRNA complexes purified from cells expressing anti-CRISPR proteins were added to the reactions at a concentration of
500 nM. Linear DNA substrates generated by restriction digestion were used at a concentration of 20 nM. Samples removed at
various time points were quenched by the addition of EDTA to a final concentration of 10 nM. Cleavage products were analyzed
on a 1.25% agarose gel stained with RedSafe (FroggaBio).
RNA cloning and sequencing
sgRNA bound to affinity purified Nme1Cas9 in the presence or absence of AcrIIA5 or in the presence of AcrIIC1were electrophoresed
on a denaturing 12.5% polyacrylamide/Urea gel and visualized by SYBRTM Gold (ThermoFisher Scientific) staining. Bands corre-
sponding to full-length sgRNA were excised for each sample and bands with higher mobility than full-length sgRNA were excised
from the sample of Nme1Cas9 purified from cells grown in the presence of AcrIIA5. The gel slices were soaked in 250 mL of DNA
Gel Elution Buffer (New England Biolabs) supplemented with 1:100 SUPERase, In RNase Inhibitor (ThermoFisher Scientific) and
rotated overnight at 4C. The eluate was filtered through a Nanosep MF 0.45 mm column (Pall Laboratory, ODM45C35). The
RNA was ethanol precipitated and reconstituted in ultrapure water. Libraries were prepared with the NEBNext Small RNA Library
Prep Set for Illumina (New England Biolabs) following the protocol provided by the manufacturer. 100 ng of immunoprecipitated
RNAwas used as starting material. The resulting DNA library was visualized using 8%PAGE and bands corresponding to the sgRNA
fragments were excised. The DNA was eluted from the excised bands by rotating overnight in DNA Gel Elution buffer at room tem-
perature. The eluate was filtered through aNanosepMF 0.45 mmcolumn and the DNAwas ethanol precipitated and resuspended in
ultrapure water. DNA fragments were then ligated to the TOPO Blunt vector (ThermoFisher Scientific), DNA was purified from single
colonies and inserts were sequenced using the M13F or M13R primers.
Assays with chemically modified sgRNA molecules
To perform assays with chemically modified sgRNA molecules, we generated a stable human HEK293T cell line that expresses
AcrIIA5 through lentiviral vector transduction and analyzed the editing efficiency of a SpyCas9/crRNA/tracrRNA ribonucleoprotein
(RNP) complex at a well-validated site within the VEGFA gene (Mir et al., 2018a). The ‘‘unmodified’’ dual crRNA/tracrRNA guide
RNA called C0:T0 has three phosphorothioates at each end of both the crRNA (C0) and the tracrRNA (T0) to help protect against
cellular exonucleases. The guide RNA referred to as ‘‘modified,’’ called C20:T2, is heavily modified: the C20 crRNA has a mix of
20-O-methyl and 20-fluoro residues, and only six unmodified ribose moieties, each of which is adjacent to a phosphorothioate modi-
fication and is RNase-resistant. The 67-nucleotide T2 tracrRNA is 82% modified, with a mix of 55 20-O-methyl and 20-fluoro resi-
dues, as well as twelve riboses. Those twelve riboses are not phosphorothioated, but they are all buried in the interior of the protein
and therefore largely protected fromRNaseswhen loaded into the SpyCas9 RNP. These chemical modifications in C20 and T2 do not
impair the genome editing efficiencies by RNP in mammalian cells (Mir et al., 2018a).
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were conducted with at least three biological replicates. Number of biological replicates are reported in the individual
Figure Legends. Error bars represent the standard deviations (Figures 2A, 2B, and 2D).
DATA AND CODE AVAILABILITY
This study did not generate unique datasets or code.
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